Randomized, Double-Blind Study to Assess Safety, Immunogenicity, and Lot Consistency of Solvay's Cell-Derived Influenza Vaccine and Its Non-Inferiority Compared to Influvac.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Abbott Laboratories; Solvay Pharmaceuticals
- 25 Aug 2011 Additional lead trial investigator (Hanka de Voogd) identified, company added as reported by ClinicalTrials.gov.
- 31 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 31 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.